ReviewClinics in liver disease2008
Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century.
Review in Clinics in liver disease, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Trial
- Determinants of stigma among patients with hepatitis C virus infection.Journal of viral hepatitis · 2020Article
- Perinatal transmission of hepatitis C virus: an update.Archives of medical science : AMS · 2020Article
- Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study.Journal of translational medicine · 2015Article
- FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.BMC medicine · 2014Article
- Mortality of patients infected with HIV in the intensive care unit (2005 through 2010): significant role of chronic hepatitis C and severe sepsis.Critical care (London, England) · 2014Article
- The next therapeutic challenge in HIV: polypharmacy.Drugs & aging · 2013Review
- Alterations in immune function are associated with liver enzyme elevation in HIV and HCV co-infection after commencement of combination antiretroviral therapy.Journal of clinical immunology · 2011Article
- New frontiers of HCV therapy in HIV/HCV co-infection.Current HIV/AIDS reports · 2010Article
- RNA interference effectively degrades mRNA and inhibits protein expression of GBV-C E2 gene in Huh7 cells.Virus genes · 2009Article
- Hepatitis C treatment experiences and decision making among patients living with HIV infection.The Journal of the Association of Nurses in AIDS Care : JANACArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Because of shared routes of transmission, hepatitis C virus (HCV) coinfection is common among HIV-infected persons. Because of the effectiveness of antiretroviral therapy, chronic HCV has now emerged as a major cause of morbidity and mortality in this population. Because chronic HCV is highly prevalent among HIV-infected patients and has a rapid disease progression, antiviral therapy with pegylated interferon plus ribavirin is critical for the long-term survival of HIV/HCV-coinfected patients. In this article, the authors review the (1) epidemiology of HCV among HIV-infected individuals, (2) effect of HIV on the natural history of chronic HCV, (3) impact of antiretroviral therapy on HCV coinfection, and (4) management of chronic HCV in the HIV-infected person.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.